Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (191-200 of 324) with videos related to

Pageof 33
Sort By:
Journal of Virology|October 24, 2008
Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set pointClive M Gray, Mandla Mlotshwa, Catherine Riou, et al.
Journal of Virology|March 11, 2011
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionElin S Gray, Maphuti C Madiga, Tandile Hermanus, et al.
The Journal of Infectious Diseases|October 13, 2004
Does tuberculosis increase HIV load?John H Day, Alison D Grant, Katherine L Fielding, et al.
Plos Pathogens|December 17, 2019
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibodySimone I Richardson, Bronwen E Lambson, Andrew R Crowley, et al.
Journal of Virology|November 21, 2008
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasmaKatie L Davis, Frederic Bibollet-Ruche, Hui Li, et al.
Plos Pathogens|September 2, 2022
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodiesCathrine Scheepers, Prudence Kgagudi, Nonkululeko Mzindle, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|August 6, 2015
Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratoryJoshua M Stolker, Michael J Lim, David M Shavelle, et al.
Antiviral Therapy|June 12, 2013
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South AfricaChristopher J Hoffmann, Johanna Ledwaba, Jin-Fen Li, et al.
BMJ Open|July 6, 2019
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trialSharana Mahomed, Nigel Garrett, Edmund Capparelli, et al.
Plos One|July 9, 2011
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infectionCynthia Firnhaber, Livio Azzoni, Andrea S Foulkes, et al.
Pageof 33

Showing results (191-200 of 324) with videos related to

Sort By:
Pageof 33
Journal of Virology|October 24, 2008
Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set pointClive M Gray, Mandla Mlotshwa, Catherine Riou, et al.
Journal of Virology|March 11, 2011
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionElin S Gray, Maphuti C Madiga, Tandile Hermanus, et al.
The Journal of Infectious Diseases|October 13, 2004
Does tuberculosis increase HIV load?John H Day, Alison D Grant, Katherine L Fielding, et al.
Plos Pathogens|December 17, 2019
IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibodySimone I Richardson, Bronwen E Lambson, Andrew R Crowley, et al.
Journal of Virology|November 21, 2008
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasmaKatie L Davis, Frederic Bibollet-Ruche, Hui Li, et al.
Plos Pathogens|September 2, 2022
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodiesCathrine Scheepers, Prudence Kgagudi, Nonkululeko Mzindle, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|August 6, 2015
Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratoryJoshua M Stolker, Michael J Lim, David M Shavelle, et al.
Antiviral Therapy|June 12, 2013
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South AfricaChristopher J Hoffmann, Johanna Ledwaba, Jin-Fen Li, et al.
BMJ Open|July 6, 2019
Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trialSharana Mahomed, Nigel Garrett, Edmund Capparelli, et al.
Plos One|July 9, 2011
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infectionCynthia Firnhaber, Livio Azzoni, Andrea S Foulkes, et al.
Pageof 33